Identification
- Summary
Capromab pendetide is a monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
- Generic Name
- Capromab pendetide
- DrugBank Accession Number
- DB00089
- Background
Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate the extent of prostate cancer.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Structure
- Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- (111In)-Capromab pendetide
- Capromab pendetide
- Indium (111In) capromab pendetide
- Indium 111 Capromab Pendetide
- Indium In 111 capromab pendetide
- External IDs
- CYT-356
- Cytogen 356
Pharmacology
- Indication
For diagnosis of prostate cancer and detection of intra-pelvic metastases.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Diagnostic agent Prostate cancer •••••••••••• •••••••••• ••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.
- Mechanism of action
Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
Target Actions Organism AGlutamate carboxypeptidase 2 other/unknownHumans - Absorption
Not Available
- Volume of distribution
- 4 ± 2.1 L
- Protein binding
Not Available
- Metabolism
Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production
- Route of elimination
Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.
- Half-life
Not Available
- Clearance
- 42 +/- 22 mL/hr
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide. Aducanumab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide. Alirocumab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Alirocumab. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- ProstaScint (Cytogen Corp.)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ProstaScint Kit for the Preparation of Indium In 111 Capromab Pendetide Kit 0.5 mg/1mL Intravenous Jazz Pharmaceuticals, Inc. 1996-10-28 2015-05-22 US 
Categories
- ATC Codes
- V09IB04 — Indium (111in) capromab pendetide
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Blood Proteins
- Compounds used in a research, industrial, or household setting
- Diagnostic Radiopharmaceuticals
- Globulins
- Immunoglobulins
- Immunoproteins
- Indicators and Reagents
- Indium (111In) Compounds
- Indium Radioisotopes
- Laboratory Chemicals
- Prostatic Neoplasms
- Proteins
- Serum Globulins
- Tumour Detection
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- BDO5072GRX
- CAS number
- 145464-28-4
References
- General References
- External Links
- PubChem Substance
- 46506263
- 136300
- ChEMBL
- CHEMBL2108285
- Therapeutic Targets Database
- DAP001049
- PharmGKB
- PA164745489
- Wikipedia
- Indium_(111In)_capromab_pendetide
- FDA label
- Download (1.65 MB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 2 Completed Diagnostic Prostate Cancer 1 1 Completed Diagnostic Prostate Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- EUSA Pharma Inc.
- Dosage Forms
Form Route Strength Kit Intravenous 0.5 mg/1mL - Prices
Unit description Cost Unit Prostascint kit 1584.0USD kit DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 61 °C (FAB fragment), 71 °C (whole mAb) Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Other/unknown
- General Function
- Tetrahydrofolyl-poly(glutamate) polymer binding
- Specific Function
- Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of fola...
- Gene Name
- FOLH1
- Uniprot ID
- Q04609
- Uniprot Name
- Glutamate carboxypeptidase 2
- Molecular Weight
- 84330.015 Da
References
- Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. [Article]
- Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. [Article]
- Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. [Article]
- Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:41